scholarly journals Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial

2019 ◽  
Vol 43 (5) ◽  
pp. 979-987 ◽  
Author(s):  
Katie Witkiewitz ◽  
Daniel E. Falk ◽  
Raye Z. Litten ◽  
Deborah S. Hasin ◽  
Henry R. Kranzler ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
World Health Organization ◽  
Alcohol Use Disorder ◽  
World Health ◽  
Health Organization

scholarly journals Compliance of clinical trial registries with the World Health Organization minimum data set: a survey

Trials ◽  
2009 ◽  
Vol 10 (1) ◽  
Author(s):  
Lorenzo P Moja ◽  
Ivan Moschetti ◽  
Munira Nurbhai ◽  
Anna Compagnoni ◽  
Alessandro Liberati ◽  
...  
Keyword(s):  
Clinical Trial ◽  
World Health Organization ◽  
World Health ◽  
Minimum Data Set ◽  
Data Set ◽  
Clinical Trial Registries ◽  
Minimum Data ◽  
The World ◽  
Health Organization

scholarly journals Consumo de álcool e qualidade de vida em idosos na saúde da família

2016 ◽  
Vol 6 (3) ◽  
Author(s):  
Sônia Maria Soares ◽  
Elenice Dias Ribeiro de Paula Lima ◽  
Madeline A. Naegle ◽  
Patrícia Aparecida Barbosa Silva ◽  
Joseph Fabiano Guimarães Santos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alcohol Use ◽  
World Health Organization ◽  
Alcohol Use Disorders ◽  
World Health ◽  
World Health Organization Quality ◽  
Identification Test ◽  
Organization Quality ◽  
Health Organization

O estudo tem como objetivo avaliar a associação entre o consumo de álcool e qualidade de vida em idosos. Trata-se de estudo transversal envolvendo idosos (n = 593), usuários de unidades básicas de saúde. Foram utilizados os instrumentos Alcohol Use Disorders Identification Test-Consumption para avaliar o consumo de álcool e World Health Organization Quality of Life-Bref para avaliar a qualidade de vida. Regressão logística foi utilizada para verificar associação entre consumo de álcool e variáveis independentes; e técnica de análise de agrupamentos para análise de possíveis grupos homogêneos entre idosos com rastreamento positivo para alcoolismo e qualidade de vida. Foi encontrado prevalência de consumo de bebida alcóolica de 8,9%. As variáveis escore Qualidade de Vida Geral < 60, depressão e faixa etária 70 a 79 anos mantiveram associação significativa com o desfecho. Obteve-se dois grupos homogêneos distintos dispostos em cinco subgrupos. Estratégias de enfrentamento devem ser contempladas nos planos de ações das políticas públicas e alerta metodológico na forma de expor a variável alcoolismo é necessário.

scholarly journals Lack of clinical trial data transparency and current solutions

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Tabassom Baghai
Keyword(s):  
Clinical Trial ◽  
Clinical Research ◽  
World Health Organization ◽  
Clinical Trial Data ◽  
Trial Data ◽  
World Health ◽  
The World ◽  
Data Transparency ◽  
Health Organization ◽  
The U.S

An ongoing challenge in clinical research is the inaccessibility of clinical trial data, which prevents physicians from making an informed decision with regards to patient care. The U.S. Food and Drug Administration (FDA) as well as the World Health Organization (WHO) recently called for all trial data to be registered and made publically available. However, this issue is still ongoing and there are several measures currently being enforced to rectify these concerns. Potential solutions, such as regulations, campaigns, and possible conse- quences, for increasing transparency in clinical trial data will be discussed. RÉSUMÉ L’inaccessibilité des données provenant d’essais cliniques constitue un défi constant en recherche clinique, puisqu’elle empêche les médecins de prendre des décisions éclairées quant aux soins de leurs patients. Récemment, le Secrétariat américain aux produits alimentaires et pharmaceutiques (FDA) ainsi que l’Organisation mondiale de la Santé (OMS) ont demandé que toutes les données d’essais cliniques soient enregistrées et mises à la disposition du public. Toutefois, ce problème persiste et plusieurs mesures ont été mises en place pour répondre à ces préoccupations. Des solutions possibles dont des réglementations, des campagnes et des sanctions possibles pour améliorer la transparence en ce qui concerne les données d’essais cliniques seront discutées. 

Sign in / Sign up

Export Citation Format

Share Document